Drug Search Results
More Filters [+]

Rezatomidine

Alternative Names: rezatomidine, AGN 203818, agn-203818, AGN XX/YY, (+)-4-(S)-[1-(2,3-Dimethyl-phenyl)-ethyl]-1,3-dihydro-imidazole-2-thione, 4[1-(2,3-Dimethyl-phenyl)-ethyl]-1,3-dihydro-imidazole-2-thione
Latest Update: 2022-03-28
Latest Update Note: News Article

Product Description

For Treatment of chronic pain (Sourced from: https://searchusan.ama-assn.org/usan/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Frezatomidine.pdf)

Mechanisms of Action: ADRA1A Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rezatomidine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Myofascial Pain Syndromes|Fibromyalgia|Cystitis, Interstitial|Pain Unspecified|Irritable Bowel Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2006-006100-11

P2

Completed

Fibromyalgia

2009-10-27

NCT00441766

P2

Terminated

Irritable Bowel Syndrome

2008-02-01

NCT00445705

P2

Terminated

Myofascial Pain Syndromes|Fibromyalgia

2008-01-01

NCT00381719

P2

Completed

Pain Unspecified

2007-11-01

Recent News Events